Latigo Biotherapeutics

Latigo Biotherapeutics is a private, clinical-stage biotech company pioneering a new class of non-opioid pain therapeutics. Its lead program, LTG-001, is a Nav1.8 inhibitor that has completed a Phase 1 trial, showing favorable safety and rapid absorption. The company leverages a proprietary discovery platform centered on human biology and ion channel expertise to develop peripherally-acting analgesics for a large and underserved market dominated by opioids.

Integrated drug discovery platform focused on human biology and ion channels. It involves target selection validated by human genetics/pharmacology, structure-based drug design optimized with in-house patch clamp electrophysiology on human neurons, and a focus on peripheral biodistribution to maximize target engagement while minimizing CNS exposure.

Latigo competes in the non-opioid analgesic space with numerous biotech and pharmaceutical companies. Key competitors include those developing Nav1.8 inhibitors (e.g., Vertex Pharmaceuticals, which has an approved Nav1.8 drug for pain), Nav1.7 inhibitors, NGF antibodies, and other novel mechanisms. Differentiation will rely on efficacy, safety, onset of action, and successful peripheral restriction.